Leerink Partners has downgraded BioNTech to "market perform" following a 24% surge in its share price. The analysts set a $113 price target, citing the stock's alignment with its discounted cash flow valuation. This downgrade comes after BioNTech shares climbed from December lows, outperforming the S&P Biotechnology Select Industry Index. The firm expects near-term volatility.

Leerink remains positive on BioNTech's long-term oncology strategy, particularly pumitamig, a bispecific antibody. However, they anticipate that clinical data confirming the value of these combinations won't be available until 2027 or later. The brokerage is also cautious due to limited upside from the company's cancer vaccine programs and expects volatile trading in the short term based on competitor data.

The firm also noted BioNTech's substantial cash position of $20.3 billion, which is expected to decline as the company continues investing in its oncology pipeline. Leerink's analysts expect more meaningful clinical readouts to begin in 2027. BioNTech's shares were trading near their 52-week high at the time of the report, suggesting a potential for a near-term correction.

The downgrade reflects a shift in sentiment after the recent rally. Investors should monitor clinical trial data from BioNTech's competitors, which could significantly impact the stock's movement. Furthermore, the company's financial results and progress with its oncology pipeline will be key factors to watch in the coming years, especially with the decline in the company's cash position.